IGHE and asthma: Based on the pathological mechanism of IgE in allergic asthma and the blocking of the IgE-mediated immune pathway, omalizumab (OMA) was approved as an anti-IgE humanized monoclonal antibody for the treatment of patients with poorly controlled moderate-to-severe asthma, and was the first targeted drug used in the field of asthma treatment [8].